The Malmberg lab partner in major cancer immunotherapy project
The Malmberg Lab is one of four partners in project that recently was awarded 31 MSEK to study and develop new technologies for cancer immunotherapy. The constellation is led by Professor Bjorn Onfelt at the Royal Institute of Technology in Sweden.
The team focus on T and NK cells and their interactions with tumor cells in both 2D and 3D models.
“One of the most exciting things with this collaboration is the interdisciplinary collaboration between biologists, clinical scientists and phycisists”, says Kalle Mamberg, who holds a Visiting Professor position at the Karolinska Institute.
The key challenge is to identify the right cells for the job of eliminating tumor cells. Onfelt Lab has developed a microchip screening platform with 30.000 wells measuring 22x22micrometer. The confined area and multiple wells allows visualization and quantification of multiple, serial interactions using advanced confocal microscopy. It holds potential to identify subpopulations of cells with increased killing capacity.
Published in Level 2 journals, first or last author from Oslo University Hospital.
Nordahl-Hansen A, Cogo-Moreira H, Panjeh S, Quintana DS(2023) Redefining effect size interpretations for psychotherapy RCTs in depression J Psychiatr Res, 169, 38-41(in press) DOI 10.1016/j.jpsychires.2023.11.009, PubMed 38000182
Lekva T, Sundaram AYF, Roland MCP, Åsheim J, Michelsen AE, Norwitz ER, Aukrust P, Gilfillan GD, Ueland T(2023) Platelet and mitochondrial RNA is decreased in plasma-derived extracellular vesicles in women with preeclampsia-an exploratory study BMC Med, 21(1), 458 DOI 10.1186/s12916-023-03178-x, PubMed 37996819
Chen Y, He L, Ianevski A, Ayuda-Durán P, Potdar S, Saarela J, Miettinen JJ, Kytölä S, Miettinen S, Manninen M, Heckman CA, Enserink JM, Wennerberg K, Aittokallio T(2023) Robust scoring of selective drug responses for patient-tailored therapy selection Nat Protoc(in press) DOI 10.1038/s41596-023-00903-x, PubMed 37996540